Autolus Therapeutics (NASDAQ:AUTL) Trading Up 8.3%

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares shot up 8.3% on Wednesday . The company traded as high as $3.90 and last traded at $3.90. 755,747 shares traded hands during trading, a decline of 45% from the average session volume of 1,378,435 shares. The stock had previously closed at $3.60.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a "buy" rating and set a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, June 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $8.70.

Autolus Therapeutics Stock Performance

The company has a market capitalization of $1.06 billion, a P/E ratio of -3.31 and a beta of 2.05. The stock has a fifty day simple moving average of $3.97 and a 200-day simple moving average of $4.29. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). Equities analysts forecast that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC bought a new position in shares of Autolus Therapeutics in the second quarter valued at about $43,000. Daiwa Securities Group Inc. raised its holdings in shares of Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock valued at $55,000 after buying an additional 15,293 shares during the last quarter. Bayesian Capital Management LP bought a new position in shares of Autolus Therapeutics in the first quarter valued at about $100,000. B. Riley Wealth Advisors Inc. bought a new position in shares of Autolus Therapeutics in the first quarter valued at about $108,000. Finally, SG Americas Securities LLC bought a new position in shares of Autolus Therapeutics in the first quarter valued at about $127,000. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.